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ABSTRACT
We recently described that the anti-apoptotic AMPK-related kinase, SNARK, 
promotes transforming growth factor (TGF)-β signaling in hepatocellular carcinoma 
(HCC) cells, as a potentially new therapeutic target. Here we explored FDA-approved 
drugs inhibiting the enzymatic activity of SNARK, using an in vitro luminescence 
kinase assay system. Interestingly, the long-used anti-alcoholism drug disulfiram 
(DSF), also known as Antabuse, emerged as the top hit. Enzymatic kinetics analyses 
revealed that DSF inhibited SNARK kinase activity in a noncompetitive manner to ATP 
or phosphosubstrates. Comparative in vitro analyses of DSF analogs indicated the 
significance of the disulfide bond-based molecular integrity for the kinase inhibition. 
DSF suppressed SNARK-promoted TGF-β signaling and demonstrated anti-HCC 
effects. The chemical and enzymatic findings herein reveal novel pharmacological 
effects of and use for DSF and its derivatives, and could be conducive to prevention and  
inhibition of liver fibrosis and HCC.
INTRODUCTION
Protein kinases are critically involved in nearly 
all cellular functions encompassing metabolism, gene 
expression, proliferation, motility, and death. Their 
dysregulation, contributes to serious diseases such 
as cancer, hypertension, Parkinson’s disease, and 
autoimmune diseases [1], which are attractive therapeutic 
targets [2]. In particular, AMP-activated protein kinase 
(AMPK) has been recognized as a key regulator of 
energy balance, related to type 2 diabetes and cancer 
[3], and AMPK-related kinases (ARKs) are also being 
increasingly recognized as modulators of cell dynamics 
and metabolism and observed to be tumor promoters 
though their physiological properties are not yet well 
understood [4].
Liver diseases including fibrosis and consequential 
hepatocellular carcinoma (HCC) remain an important 
health menace [5], in urgent need of improved methods 
for prophylactic and therapeutic management [6]. 
We recently reported that sucrose-non-fermenting 
protein kinase 1 (SNF1)/AMPK-related protein kinase 
(SNARK), the fourth member of 14 ARKs [7], supported 
replication of hepatitis C virus (HCV), a causative agent 
of HCC, in genome-wide RNAi screen [8], and enhanced 
profibrogenic transforming growth factor (TGF)-β 
signaling in HCC cells [9], suggesting SNARK as an 
attractive pharmacological target. Hence we here sought to 
find repositionable approved drugs [10] inhibiting SNARK 
kinase activity implementing an in vitro luminescence 
kinase assay system. Interestingly, the top hit in an 
FDA-approved drug library was disulfiram (DSF), the 
long-used anti-alcoholism drug also known as Antabuse. 
Enzymatic kinetics analyses revealed that DSF inhibited 
SNARK kinase activity in a noncompetitive manner to 
ATP or phosphosubstrates. While a close DSF analog 
tetramethylthiuram disulfide (TR) exerted inhibition, 
its monosulfide analog tetramethylthiuram monosulfide 
(TMTM) did not, indicating the significance of the 
disulfide bond-based molecular integrity of DSF for the 
kinase inhibition. DSF was indeed proved in cell culture 
to suppress SNARK-enhanced TGF-β signaling monitored 
through plasminogen activator inhibitor (PAI)-1 activity. 
DSF also exhibited anti-HCC effects, to which HCC cells 
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were conferred resistance by excessive supply of SNARK. 
The successful discovery of a SNARK inhibitor here 
discloses a novel mode to explain the recently recognized 
anti-cancer effects and anti-fibrogenic potential of DSF 
[11, 12]. These chemical and enzymatic findings will be 
conducive to prevention and inhibition of liver fibrosis 
and HCC.
RESULTS
Screen for SNARK kinase inhibitors in vitro
To confirm the validity of the in vitro SNARK 
kinase assay system, which reports the amount of ATP 
consumed for phosphorylation as luminescent signals, we 
first tested the effects of staurosporine (STS), a known 
multi-protein kinase inhibitor [13], and consequently 
observed significantly decreased luminescence by STS 
(Figure 1A), authenticating the monitoring method. Next 
we implemented the kinase assay for 636 compounds in 
the FDA-Approved Drug Screen-well Library (Figure 
1B); only three compounds demonstrated inhibition more 
than 90% in the primary screen and the top hit with around 
97% inhibition was DSF, the long-used anti-alcoholism 
drug also known as Antabuse (Figure 1C). DSF was 
structurally independent from other hits with inhibition 
more than 50% (Supplementary Figure S1A and S1B). 
The robust inhibition by DSF more potent than other high-
ranking candidates was validated separately, with the dose-
dependent effects giving 50% inhibitory concentration 
(IC
50
) of 43.7 μM in vitro (Figure 1D), while luciferase 
activity itself was not suppressed by DSF (Supplementary 
Figure S1C) in agreement with the previous counter-
screen [14].
Kinetics and modes of SNARK kinase inhibition 
by DSF
In order to clarify the mode of SNARK inhibition 
by DSF, enzymatic kinetics in the presence of DSF 
were investigated. The Michaelis-Menten plots of the 
kinase reaction with various concentrations of ATP 
(Figure 2A) implied non-competitive inhibition against 
ATP, which was confirmed by the Lineweaver-Burk 
and Dixon plots (Figure 2B and 2C, Km = 19.3 ± 2.18 
μM, Ki = 65.7 ± 6.09 μM). In addition, the reaction 
was also examined with various concentrations of the 
phosphosubstrate peptide CHKtide, whose kinetics 
are shown in the Michaelis-Menten plots (Figure 2D), 
with Km = 48.9 ± 4.23 μM. The Lineweaver-Burk and 
Dixon plots revealed non-competitive inhibition against 
the phosphosubstrates (Figure 2E and 2F, Ki = 64.3 ± 
5.17 μM), confirmed by no observation of competitive 
inhibition after the preincubation of the kinase with DSF 
either (Supplementary Figure S2).
Next, to address the question of the functional 
groups responsible for the inhibition, the effects of the 
close DSF analogs TR and TMTM (Figure 3A), on the 
kinase reaction were tested; in actuality TR inhibited the 
kinase activity with the IC
50
 42.0 μM (Figure 3B), and the 
Michaelis-Menten (Figure 3C), Lineweaver-Burk (Figure 
3D), and Dixon (Figure 3E) plots (Km = 21.8 ± 1.54 μM, 
and Ki = 79.0 ± 5.25 μM) suggested ATP-noncompetitive 
inhibition. Again kinase assays at various CHKtide 
concentrations produced the Michaelis-Menten (Figure 
3F), Lineweaver-Burk (Figure 3G), and Dixon (Figure 
3H) plots (Km = 51.2 ± 5.00 μM, Ki = 138.0 ± 21.3 μM), 
indicating phosphosubstrate-noncompetitive inhibition. 
Meanwhile TMTM exhibited almost no inhibitory 
activities (Figure 3I) up to 1000 μM (Supplementary 
Figure S3A) and hence the disulfide bond was exhibited 
in vitro to be important for DSF to inhibit the SNARK 
kinase activity. With respect to the DSF metabolite 
diethyldithiocarbamate (DDC) (Figure 3A) [15], no 
inhibitory effects were displayed (Figure 3J) while only 
slight inhibition was observed at higher concentrations 
than 100 μM (Supplementary Figure S3B), and neither did 
S-Methyl-N, N-diethylthiocarbamoyl sulfoxide (DETC-
MeSO) (Figure 3K), a further metabolite downstream of 
DDC and the known inhibitor of aldehyde dehydrogenase 
[15], inhibit the kinase activity in vitro up to 100 μM 
(Figure 3L) with mild inhibition at higher concentrations 
(Supplementary Figure S3C), wherefore biochemical 
significance of the DSF structure was confirmed. Thus 
enzymatic kinetics and chemical structure analyses 
uncovered the ATP- and phosphosubstrate-noncompetitive 
modes of SNARK inhibition by DSF via disulfide bond-
based molecular integrity (Supplementary Table S1).
Inhibition of SNARK-promoted TGF-β signaling 
by DSF
As we recently reported that SNARK enhanced 
TGF-β signaling in HCC cells and the pharmacological 
inhibition of SNARK resulted in the suppression of 
profibrogenic signaling [9], the effects of DSF were next 
assessed in cell culture. The activity of a plasmid PAI/L 
encoding a luciferase reporter gene driven by promoter 
sequences of PAI-1, a transcriptional target of TGF-β 
[16], was enhanced by SNARK overexpression and the 
effects were further highlighted by TGF-β in HepG2 cells 
(Figure 4A, white bars) in accordance with our previous 
data [9]. DSF suppressed the SNARK-promoted luciferase 
activities in the absence and particularly presence of 
TGF-β (Figure 4A, black bars), endorsing the inhibitory 
efficacy in vitro, while no inhibition of luciferase activity 
itself by DSF was confirmed in HepG2 cells with the 
overexpression of luciferase protein (Supplementary 
Figure S4A). In turn, RNAi-mediated knockdown of 
SNARK expression decreased PAI/L activity whether 
treated with TGF-β or not (Figure 4B, white bars) 
consistent with past report [9], and the suppressive effects 
by DSF on PAI/L were relatively blunted (Figure 4B, black 
bars), indicating the dependence of the DSF-mediated 
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TGF-β signaling inhibition on SNARK. Subsequently, the 
DSF analogs TR and TMTM with and without SNARK 
kinase inhibitory activity in vitro, respectively, were 
tested in the same setting. TR inhibited the SNARK-
enhanced PAI/L activity, demonstrating all the more 
pronounced effects in the presence of TGF-β (Figure 
4C), while TMTM did not affect PAI/L significantly 
(Figure 4D). Intriguingly, DDC, a key metabolite of 
DSF, decreased the PAI/L activity as well in the presence 
of TGF-β (Figure 4E) unlike DETC-MeSO (Figure 4F) 
though the both lacked the kinase inhibitory properties in 
vitro (Figure 3J and 3L). Therefore, possibly responsible 
factors such as other DDC metabolites than DETC-
MeSO and/or intracellular biological effects of DDC 
Figure 1: The SNARK kinase inhibitor screen in vitro. A. The in vitro SNARK kinase assay system was validated using the known 
multi-kinase inhibitor STS as the control. B. The kinase assay was performed for 636 compounds in the FDA-Approved Drug Screen-well 
Library. Z scores of relative kinase activities in the presence of individual drugs compared with DMSO controls are indicated. C. The 
chemical structure of DSF retrieved from the database ChemSpider. D. The kinase inhibitory effects of DSF were examined at 0.001, 0.01, 
0.1, 0.2, 1, 2, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100 μM in vitro.
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without excluding SNARK-independent mechanisms 
are implied. Noteworthily observed, on the other hand, 
was the suppression of SNARK mRNA levels in HepG2 
cells treated by DDC (Figure 4G), which could affect 
SNARK-stimulated cell biological phenotypes as TGF-β 
was found to upregulate SNARK expression levels (Figure 
4H), though such pronounced effects were not directly 
evoked by the treatment with DSF and TR (Supplementary 
Figure S4B and S4C). Additionally, the replication of 
the profibrogenic virus HCV, dependent on SNARK 
[9], was also abrogated by DSF (Supplementary Figure 
S4D), which was supported by a recent report using HCV 
replicon cells [17]. Overall, DSF’s inhibition of the in 
vitro kinase activity results in its suppression of SNARK-
dependent profibrogenic signaling in HCC cells.
Inhibition of SNARK-promoted HCC cell 
proliferation by DSF
SNARK has been found to operate against 
apoptosis, functioning as a tumor promoter [18, 19]. 
Meanwhile, the anti-cancer effects of DSF have been 
Figure 2: Enzymatic kinetics of SNARK kinase inhibition by DSF. The in vitro SNARK kinase assay was performed with 25, 
50, 100, and 250 μM ATP or 14.8, 37.0, 74.0, and 148 μM CHKtide in the presence of 0, 20, and 40 μM DSF. Subsequently effects of DSF 
on enzymatic kinetics of SNARK were calculated, yielding Michaelis-Menten plots A. and D. Lineweaver-Burk plots B. and E. and Dixon 
plots C. and F.
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Figure 3: DSF analogs and enzymatic kinetics of SNARK kinase inhibition by TR. A. Chemical structures of TR, TMTM, 
and DDC were retrieved from ChemSpider. B. Similarly to Figure 1D, the kinase inhibitory effects of TR were examined at 0.001, 0.01, 
0.1, 1, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100 μM in vitro. Similarly to Figure 2, the in vitro SNARK kinase assay was performed with 
25, 50, 100, and 250 μM ATP or 14.8, 37.0, 74.0, and 148 μM CHKtide in the presence of 0, 20, and 40 μM TR. Subsequently effects of TR 
on enzymatic kinetics of SNARK were calculated, yielding Michaelis-Menten plots. 
(Continued )
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Figure 3 (Continued ): C. and F. Lineweaver-Burk plots D. and G. and Dixon plots E. and H. Similarly to (B), effects of TMTM and 
DDC, and DETC-MeSO K. on SNARK kinase activity were examined at 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100 μM I. and J. and 100 
μM L. respectively.
described recently [12]. Hence we examined anti-HCC 
effects of DSF and presumed participation of SNARK 
in this mode of action. In HepG2 cells treated for 48h 
(Figure 5A), DSF markedly inhibited HCC cell growth 
at 20 μM as did TR relatively moderately, in contrast to 
TMTM exerting no effects at even higher concentrations, 
in proportion to its in vitro kinase inhibitory activity. DDC 
exerted pronounced anti-proliferative effects similarly to 
DSF though DDC itself was known to possess anti-cancer 
activities [20] independently. Correspondingly, remarkable 
cytotoxicities were caused by DSF and DDC while TR and 
TMTM exerted milder and no cytotoxicities, respectively 
(Supplementary Figure S5A). In the other liver cancer cell 
line PLC/PRF/5, generally the effects of DSF and TR were 
stronger than those of TMTM, though DDC exhibited a 
unique profile (Figure 5B). These data suggest that DSF 
and TR demonstrate stronger cytotoxicity, particularly at 
higher doses (Supplementary Figure S5B), while Huh7 
cells are highly susceptible to DSF (Supplementary Figure 
S5C), being inhibited by about 90% even at 10 μM, below 
the concentrations used for the cell-based assays in HepG2 
and PLC/PRF/5 cells. Meanwhile, the levels of cell 
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proliferation (Supplementary Figure S5D) and cytotoxicity 
(Supplementary Figure S5E) of PXB cells, normal human 
hepatocytes isolated from chimeric mice with a humanized 
liver (PXB mice) [21], were minimally altered, supporting 
the liver cancer cell-specific toxicity of DSF.
To determine whether SNARK was involved in 
the anti-HCC effects by DSF, we next conducted the 
assay in the presence of SNARK overexpression. Both 
HepG2 and PLC/PRF/5 cells were conferred resistance 
to DSF at lower concentrations (Figure 5C and 5D) by 
the excessive supply of SNARK (Supplementary Figure 
S5F), which was not observed with the kinase-dead K81M 
and unphosphorylated T208A mutants [9] in HepG2 
cells (Supplementary Figure S5G) and PLC/PRF/5 cells 
(Supplementary Figure S5H), confirming SNARK as 
a tumor promoter and a pharmacological target. Taken 
together, DSF exhibited anti-cancer effects against HCC 
as well, through its actions on SNARK.
Figure 4: Inhibition of SNARK-promoted TGF-β signaling by DSF. A. HepG2 cells were transfected with PAI/L and pRL-TK in 
combination with pEBMulti-Puro (Vehicle) or pEBMP-SNARK-3×FL (SNARK), followed by the treatment with DSF at 15 μM and TGF-β 
at 10 ng/mL 24 h later. On the next day the cells were lysed and the firefly and Renilla luciferase activities were measured. B. HepG2 cells 
were transfected with non-targeting siRNAs (siNT3) or siRNAs to SNARK (siSNARK), followed by transfection with PAI/L and pRL-TK 
24h later. On the next day DSF at 10 μM and TGF-β at 10 ng/mL were added and 24h later the cells were lysed and the firefly and Renilla 
luciferase activities were measured. Similarly to (A), the assays were performed using TR C. TMTM D. DDC.
(Continued )
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DISCUSSION
Growing evidence has demonstrated that SNARK 
possesses anti-apoptotic properties [18, 19] and is involved 
in cancer [22–24]. We recently reported the novel feature 
of SNARK as a profibrogenic factor in HCC cells through 
the promotion of TGF-β signaling [9]. Therefore the 
successful identification of DSF to inhibit SNARK kinase 
offers real opportunity to exploit the drug and dissect the 
mechanisms for further pharmacological development. 
An understanding of the basic enzymatic and biochemical 
properties of the SNARK-DSF interaction is important.
The enzymatic kinetics analyses suggested that 
DSF is an ATP-noncompetitive inhibitor (Figure 2), 
implying that DSF could target a regulatory site(s) for 
ATP hydrolysis rather than compete at the ATP-binding 
site. Also noncompetitively inhibited was CHKtide, 
connoting that a modulatory domain distinct from the 
catalytic center is the DSF target. It is very interesting 
to speculate that an identical regulatory site could affect 
both ATP and CHKtide reactions, though behaviors of 
actual proteins catalyzed in cells may not be entirely 
reflected by CHKtides. The identification of potential 
DSF-binding targets of SNARK is of great interest; the 
Figure 4 (Continued ): E. and DETC-MeSO F. in place of DSF. Total RNA was extracted from HepG2 cells treated with DDC at 
indicated concentrations G. or 10 ng/mL TGF-β H. for 48h and SNARK mRNA levels were quantified by qRT-PCR with normalization to 
GAPDH. n ≥ 3. Error bars = SD.
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close DSF analog TR shared a similar 3D structure with 
and retained the in vitro kinase inhibitory activity in the 
same manner as DSF. However, TMTM, the monosulfide 
analog of TR, was conformationally distinct from DSF 
and TR and devoid of the kinase inhibition. The disulfide 
bond-based structure is assumed to be fit for DSF docking 
with the kinase, and accordingly further structural analyses 
including crystallography of SNARK and its complex with 
DSF are warranted based on the insights from DSF and its 
analogs as chemical probes. This could stimulate rational 
drug development through the well-known characteristic 
of DSF.
In our assays, SNARK was shown to promote 
TGF-β signaling in HCC cells, which was suppressed by 
the SNARK inhibitor DSF as expected. Intriguingly, a 
recent study reported that DSF inhibited TGF-β-induced 
epithelial-mesenchymal transition in breast cancer cells 
[11] in conformity with the downregulation of TGF-β 
signaling by DSF in zebra fish cells [25]. Furthermore, 
fibrosis-attenuating properties of DSF were observed 
in a mouse model of non-alcoholic steatohepatitis [26]. 
Therefore SNARK has been projected as the target of 
anti-fibrogenic effects through TGF-β signaling by DSF. 
As for DDC, a DSF metabolite, though it lacks SNARK 
kinase inhibition in vitro, suppressive effects on PAI/L 
when treated with TGF-β were still detected, potentially 
indicating intracellular circumstance-specific suppression 
of TGF-β signaling. Of interest, DDC, but not DSF 
(Supplementary Figure S4B), was found to decrease 
the SNARK expression levels (Figure 4G), which was 
in actuality elevated by TGF-β (Figure 4H). This could 
at least partly explain the retained suppressive effects 
of DDC particularly in the presence of TGF-β, and 
denoted the effectiveness of breaking the vicious circle of 
reciprocal upregulation between SNARK and TGF-β. The 
enzymatic and expression inhibition of SNARK by DSF 
and its metabolite DDC, respectively, are thus postulated 
to accentuate the potency of DSF coordinately, and further 
detailed mechanistic studies are underway to decipher 
these findings.
The noted function of SNARK as a tumor promoter 
with anti-apoptotic properties was indeed verified in 
HCC cells through observation of their resistance to 
the cytotoxic effects of DSF conferred by the excessive 
supply of SNARK. In recent years, mounting evidence 
suggests anti-cancer properties of DSF across cancer 
types [12], and HCC cells are no exception; DSF exerted 
anti-HCC effects through inhibition of hypoxia-induced 
Figure 5: Inhibition of SNARK-promoted HCC cell proliferation by DSF. HepG2 A. and PLC/PRF/5 B. cells were treated 
with DSF, TR, TMTM, and DDC at the indicated doses for 24 hours and the relative cell viabilities to untreated control cells were measured 
by CCK-8 assay. pEBMulti-Puro (Vehicle) or pEBMP-SNARK-3×FL (SNARK) was transfected into HepG2 C. or PLC/PRF/5 D. cells, 
followed by DSF treatment at the indicated concentrations 48h later. On the next day the relative cell viabilities to the control samples 
untreated and transfected with pEBMulti-Puro were measured similarly to (A) and (B). *P < 0.05 by Student’s t-test. n = 4. Error bars = SD.
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gene expression and hypoxia-inducible factor activity for 
tumor adaptation to hypoxia [27]. Also tumorigenicity 
of tumor-initiating HCC cells was impaired via reactive 
oxygen spieces-p38 pathway and Glypican 3 by DSF 
[28]. Another recent study showed DSF, in Hep3B 
cells, triggered apoptosis intrinsically and extrinsically, 
including activation of the pathway through death 
receptor CD95 [29], through which SNARK reportedly 
rendered breast cancer cells apoptosis-resistant and 
invasive [18]. Such modes of anti-cancer actions by DSF 
as above allude to critical molecules associated with and 
potentially phosphorylated as substrates by SNARK, 
whose unknown functions attract much attention for 
reciprocal elucidation between physiological roles and 
therapeutic implications. Again DDC, with anti-cancer 
effects via chelating into metal ions [20] and reported 
to significantly improve the overall survival in breast 
cancer patients [30], demonstrated unique profiles of 
cytotoxicity to HCC cells, and indicated the effects by 
DSF are to be kept even after being metabolized at least 
reducing SNARK expression (Figure 4G); lately further 
improvement in stable delivery and anti-cancer effects of 
DDC was reported in vivo [31]. Utilization of intact DSF, 
simultaneously, is being investigated for its anti-cancer 
properties, and such a method was recently developed by 
nanocapsule-protected medicine [32], achieving favorable 
anti-cancer effects. Still the cytotoxic efficacy could 
fluctuate depending on individual cell types with various 
genetic and pathoetiological backgrounds as was the 
case with PLC/PRF/5 cells positive for hepatitis B virus 
proteins (Figure 4B) and anti-cancer agents [33]. Thus, 
together with the observation of suppressive effects on 
TGF-β signaling, leading to the inhibition of cancer cell 
metastasis and tumor growth in vivo [11], DSF is thought 
to be an effective therapeutic agent for solid tumors 
including HCC.
In practice, therapeutic effects of DSF have 
been observed in metastatic non-small cell lung 
cancer (NSCLC) patients with an increase in survival 
[34] and solid tumors [35], and also is under clinical 
trials for glioblastoma [12, 36] and advanced HCC 
(UMIN000008529, http://www.umin.ac.jp/) in expectation 
of exploitation as a chemotherapeutic agent. Another 
attractive feature of DSF is the tolerability and safety 
demonstrated over years of clinical experience with a 
large number of patients, and also in the NSCLC patients 
[34]. Plasma concentrations of DSF in several reports [37, 
38], reaching even above 100 μM, routinely exceeded 
the IC
50
 of the in vitro kinase assay described here, so 
SNARK inhibitory concentrations are expected to be 
achieved safely in patients. It should be cautioned that the 
possible novel clinical use of DSF would be in persons 
with chronic liver disease at risk for cirrhosis and HCC, 
and understandably toxicity would need to be carefully 
monitored especially in persons with advanced cirrhosis, 
as summarized in disease guidelines [39]. However, DSF 
has long been used safely in patients who often harbor 
significant alcoholic liver disease.
Here the enzymatic inhibition of SNARK and 
resultant anti-TGF-β/HCC effects by DSF provide us with 
new biochemical and pragmatic insights. The utility and 
a newly revealed property of DSF were mechanistically 
suggested and in turn the significance of regulatory 
sites for SNARK kinase activity as validated drug 
target can now be comprehensively assessed using DSF 
as a chemical probe. Also DSF derivatives with better 
potencies could be examined [40] in addition to devising 
improved methods of delivery [32, 41]. Further chemical 
and biological analyses would accelerate understanding 
of SNARK functions and at the same time the chemical 
search for and development of potent SNARK inhibitors 
continue. Finally well-tolerated and more effective 
regimens for HCC management can be expected to be 
developed using DSF and its analogs/derivatives, inspired 
and reinforced by the discovery in this study.
MATERIALS AND METHODS
Compounds and cells
DSF, and STS, TR, TMTM and Sodium 
diethyldithiocarbamate trihydrate were purchased from 
Selleckchem (Houston, TX) and Sigma-Aldrich (St. Louis, 
MO), respectively. DETC-MeSO was purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA). TGF-β was 
purchased from R&D (Minneapolis, MN). Antibodies to 
luciferase, HCV NS3, and FLAG and β-actin (ACTB) were 
purchased from MBL (Aichi, Japan), Abcam (Cambridge, 
United Kingdom), and Sigma-Aldrich, respectively. 
The FDA-Approved Drug Screen-well Library and Cell 
Counting Kit (CCK)-8 were obtained from Enzo Life 
Sciences (Farmingdale, NY) and Dojindo (Kumamoto, 
Japan), respectively. Cytotoxicities of compounds were 
determined with the LDH cytotoxicity detection kit 
(Takara Bio, Shiga, Japan). HepG2, PLC/PRF/5, and 
Huh7 cells were cultured according to the protocols of 
American Type Culture Collection (Manassas, VA) and 
Japanese Collection of Research Bioresources Cell Bank 
(Osaka, Japan). The cell lines were authenticated by short 
tandem repeat method (Bex, Tokyo, Japan) in Jan 2016. 
PXB cells were purchased from Phoenix Bio (Hiroshima, 
Japan). JFH1 virus infection was performed as described 
previously [9].
Plasmid
pCMV14-SNARK_NCBI-3×FL was constructed 
by primers EcoRI-SNARK-F 5′-TTGAATTCGGCCA 
CCATGGAGTCGCTGGTTTTC-3′, XbaI-SNARK-ΔT 
GA-R 5′-AATTCTAGAGGTGAGCTTTGAGCAGAC 
-3′, SNARK-1323-G-F 5′-GGCAGGCTGCCCCGCTG 
CTC-3′, and SNARK-1323-G-R 5′-GAGCAGCGGGGCA 
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GCCTGCC-3′, using pCMV14-SNARK-3×FL as a template 
[9]. Sequences containing SNARK open reading frame 
were amplified by the primers XhoI- SNARK-F 5′-ATTC
TCGAGGGCCACCATGGAGTCGCTGGTTTTC-3′ and 
NotI-SNARK-3×FL-R 5′-AATGCGGCCGCCTACTTGT
CATCGTCATCCTTG-3′ from pCMV14- SNARK_NCBI-
3×FL, and subcloned into pEBMulti-Puro (Wako, Osaka, 
Japan), producing the expression plasmid pEBMP-SNARK-
3×FL. Similarly, pCMV14-SNARK(K81M)_NCBI-
3×FL and pCMV14-SNARK(T208A)_NCBI-3×FL were 
generated by primers EcoRI-SNARK-F, XbaI-SNARK-
ΔTGA-R, SNARK-1323-G-F and SNARK-1323-G-R 
using pCMV14-SNARK(K81M)-3×FL and pCMV14-
SNARK(T208A)-3×FL as templates, respectively [9]; 
subsequently using these constructs as templates, pEBMP-
SNARK(K81M)-3×FL and pEBMP-SNARK(T208A)-
3×FL were produced by primers EcoRI-SNARK-F and 
NotI-SNARK-3×FL-R. pEBMP-Luc was constructed by 
primers XhoI-Luc-F 5′-ATTCTCGAGGGCCACCATGG
AAGACGCCAAAAACATAAAGAAAGGC-3′ and NotI-
Luc-R AATGCGGCCGCTTACAATTTGGACTTTCCGC
CCTTCTTGGC using PAI/L as a template.
In vitro kinase assay
NUAK2 Kinase Enzyme System was purchased 
from Promega (Madison, WI). Kinase assay was 
performed according to the manufacturer’s protocol and 
the luminescence was monitored (n = 4). Briefly, 12.5 ng of 
recombinant SNARK was incubated with CHKtide and ATP, 
in the presence or absence of DMSO or compounds, for 60 
min at room temperature, followed by ATP depletion and 
subsequent detection of converted ADP via luminescence.
Enzyme kinetic analysis
The mode of enzymatic inhibition was calculated 
bySigmaplot (Systat Software, San Jose, CA), with the 
best fit models determined by the Akaike Information 
Criterion.
Luciferase assay
Firefly luciferase activity was monitored by a dual-
luciferase reporter assay system (Promega) and normalized 
to Renilla luciferase activities from pRL-TK as described 
previously [9]. SiNT3 (#D-001210-03) and siSNARK 
(SI02660224) were purchased from GE Healthcare Bio-
Sciences (Pittsburgh, PA) and QIAGEN (Valencia, CA), 
respectively, and the assay was performed as described 
previously [9], with 3 pmol siRNAs at 5 nM.
Quantitative reverse transcription-polymerase 
chain reaction
Relative mRNA and viral RNA levels were quantified 
as previously described [9] using the following primer sets: 
SNARK-F 5′-GATGCACATACGGAGGGAGAT-3′ and 
SNARK-R 5′-GCTGGCATACTCCATGACGAT-3′ for 
SNARK, JFH1-F 5′-CTGTCTTCACGCAGAAAGCG-3′ 
and JFH1-R 5′- TCGCAACCCAACGCTACTCG-3′ and 
GAPDH-F2 5′-AAGGTGAAGGTCGGAGTCAAC-3′ and 
GAPDH-R2 5′-GGGGTCATTGATGGCAACAATA-3′ for 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
with the value of SNARK and JFH1 normalized to that of 
GAPDH.
Western blotting
Total protein was resolved by SDS-PAGE and 
subjected to western blotting as described previously [9].
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